 In a clinical Phase 12 dose ranging study CA040, NCT003980860, nab-paclitaxel plus gemcitabine CA040, NCT003980860 antitumor activity and tolerability were established in patients who had no prior treatment for metastatic pancreatic cancer. The maximum tolerated dose and recommended dose for further studies was determined to be 125 mgm2 nab-paclitaxel in combination with 1000 mgm2 gemcitabine. 